je.st
news
Tag: samsung
Hedge fund, Samsung Group locked in fight over $8 billion merger
2015-06-11 05:18:11| Semiconductors - Topix.net
U.S. activist hedge fund Elliott filed another injunction to block a proposed $8 billion merger of two key Samsung Group companies, escalating a conflict over a deal seen key to leadership transfer at South Korea's top conglomerate. Elliott said it had filed its second injunction with a South Korean court, this time to stop builder Samsung C&T Corp from selling treasury shares amounting to a 5.8 percent stake to KCC Corp in a bid to gain KCC's support for the proposed all-share takeover offer from Cheil Industries Inc. In a statement, Samsung C&T said the sale would defend shareholders against "an attack from a foreign hedge fund intended for a short-term trading profit".
Tags: group
samsung
fight
fund
Hedge fund, Samsung Group locked in fight over $8 billion merger
2015-06-11 05:12:52| Electronics - Topix.net
U.S. activist hedge fund Elliott filed another injunction to block a proposed $8 billion merger of two key Samsung Group companies, escalating a conflict over a deal seen key to leadership transfer at South Korea's top conglomerate. Elliott said it had filed its second injunction with a South Korean court, this time to stop builder Samsung C&T Corp from selling treasury shares amounting to a 5.8 percent stake to KCC Corp in a bid to gain KCC's support for the proposed all-share takeover offer from Cheil Industries Inc. In a statement, Samsung C&T said the sale would defend shareholders against "an attack from a foreign hedge fund intended for a short-term trading profit".
Tags: group
samsung
fight
fund
Samsung Galaxy S6 (AT&T)
2015-06-11 03:01:56| PC Magazine Cell Phones Product Guide
The Galaxy S6 puts Samsung back on top with the best screen, processor, and body design of any Android-powered phone.
Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints
2015-06-10 14:46:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. & SEOUL, South Korea Data Presented for the First Time at the EULAR Annual Meeting Phase 1 Data for SB2, SB4 and SB5, an Investigational Biosimilar of Humira (Adalimumab), also Presented KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical studies of SB4, an investigational biosimilar of Enbrel (etanercept), and SB2, an investigational biosimilar of Remicade (infliximab), met their primary endpoints, demonstrating equivalence to the originator medicine in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy. Language: English Contact: Merck Media:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orMerck Investors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879orSamsung Bioepis Media:Jamyung Cha, (82) 32-455-6137orSamsung Bioepis Investors:Sungjoon Park, (82) 32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: met
primary
studies
phase
Excelerate Energy scraps $2bn FLNG vessel order with Samsung Heavy Industries
2015-06-10 01:00:00| Offshore Technology
US-based Excelerate Energy has cancelled its plans to order for a $2bn floating liquefaction storage and offloading (FLNG) vessel from Samsung Heavy Industries.
Tags: order
energy
heavy
samsung
Sites : [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] [265] [266] [267] [268] [269] [270] next »